A detailed history of Wedbush Securities Inc transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Wedbush Securities Inc holds 13,185 shares of DVAX stock, worth $169,427. This represents 0.01% of its overall portfolio holdings.

Number of Shares
13,185
Previous 14,530 9.26%
Holding current value
$169,427
Previous $163,000 9.82%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$10.05 - $11.61 $13,517 - $15,615
-1,345 Reduced 9.26%
13,185 $147,000
Q2 2024

Aug 06, 2024

SELL
$10.73 - $12.58 $43,456 - $50,949
-4,050 Reduced 21.8%
14,530 $163,000
Q1 2024

May 14, 2024

BUY
$11.7 - $14.98 $36,036 - $46,138
3,080 Added 19.87%
18,580 $231,000
Q2 2023

Aug 14, 2023

SELL
$9.85 - $13.17 $19,700 - $26,340
-2,000 Reduced 11.43%
15,500 $200,000
Q4 2022

Jan 31, 2023

SELL
$10.27 - $13.29 $20,540 - $26,580
-2,000 Reduced 10.26%
17,500 $186,000
Q3 2022

Oct 18, 2022

SELL
$9.93 - $17.44 $9,930 - $17,440
-1,000 Reduced 4.88%
19,500 $203,000
Q1 2022

Apr 19, 2022

SELL
$9.75 - $14.44 $4,875 - $7,220
-500 Reduced 2.38%
20,500 $222,000
Q4 2021

Jan 13, 2022

BUY
$13.17 - $20.94 $39,510 - $62,820
3,000 Added 16.67%
21,000 $295,000
Q3 2021

Oct 08, 2021

SELL
$9.16 - $19.83 $143,812 - $311,331
-15,700 Reduced 46.59%
18,000 $345,000
Q2 2021

Jul 27, 2021

BUY
$7.25 - $10.99 $52,200 - $79,128
7,200 Added 27.17%
33,700 $331,000
Q1 2021

Apr 26, 2021

SELL
$4.57 - $11.18 $13,710 - $33,540
-3,000 Reduced 10.17%
26,500 $260,000
Q4 2020

Feb 16, 2021

BUY
$3.73 - $5.6 $18,650 - $28,000
5,000 Added 20.41%
29,500 $131,000
Q3 2020

Oct 20, 2020

BUY
$4.32 - $11.7 $38,880 - $105,300
9,000 Added 58.06%
24,500 $106,000
Q2 2020

Jul 16, 2020

BUY
$2.94 - $9.1 $14,700 - $45,500
5,000 Added 47.62%
15,500 $137,000
Q2 2019

Aug 01, 2019

BUY
$3.65 - $7.89 $38,325 - $82,845
10,500 New
10,500 $42,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.63B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Wedbush Securities Inc Portfolio

Follow Wedbush Securities Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wedbush Securities Inc with notifications on news.